97175 ⎘
Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants against the immunoglobulin superfamily against B7 molecules, e.g. CD80, CD86
Anti-B7-H3 monoclonal antibody and use thereof in cell therapy
#1502ANTI-PD-1 VACCINE COMPOSITION
#1503TREATMENT WITH ANTI-TIGIT ANTIBODIES AND PD-1 AXIS BINDING ANTAGONISTS
#1504Checkpoint blockade and microsatellite instability
#1505Crystalline forms of a CD73 inhibitor and uses thereof
#1506INTRALESIONAL ADMINISTRATION OF PD-1 INHIBITORS FOR TREATING SKIN CANCER
#1507METHOD AND MEDICAMENT FOR TREATING CANCER UNRESPONSIVE TO PD-1/PD-L1 SIGNALING INHIBITOR
#1508ANTIGEN BINDING AGENTS THAT BIND CD277 AND USES THEREOF
#1509Chimeric protein comprising an interferon alpha 2mutant and a PD-L1 binding moiety
#1510A MULTISPECIFIC ANTIBODY AND PREPARATION METHOD AND USE THEREOF
#1511Novel Rationally Designed Protein Compositions
#1512Bicyclic compounds and their use in the treatment of cancer
#1513HUMAN ANTIBODIES TO PD-L1
#1514MULTIVALENT IgM- AND IgA-Fc-BASED BINDING MOLECULES
#1515DE-ADCC/CDC FUNCTIONS OF ANTIBODIES AND THEIR APPLICATIONS
#1516Anti-PD-L1 antibodies
#1517Anti-PD-L1 antibody and use thereof
#1518VISTA ANTIGEN-BINDING MOLECULES
#1519STING AGONIST COMBINATION TREATMENTS WITH IMMUNE CHECKPOINT INHIBITORS
#1520METHODS OF TREATING TUMOR
#1521Costimulatory B7-H1 in renal cell carcinoma patients: indicator of tumor aggressiveness and potential therapeutic target
#1522MULTIFUNCTIONAL MOLECULES THAT BIND TO T CELL RELATED CANCER CELLS AND USES THEREOF
#1523MULTIFUNCTIONAL MOLECULES THAT BIND TO CALRETICULIN AND USES THEREOF
#1524DASATINIB AND ANOTHER 5-THIAZOLECARBOXAMIDE KINASE INHIBITOR, AND USES THEREOF
#1525Chimeric antigen receptors with mutated CD28 phosphorylation sites
#1526ANTI-TNFR2 ANTIBODIES AND USES THEREOF
#1527Anti PD-L1 antibodies
#1528ANTI-PD-1 VACCINE COMPOSITION
#1529ANTIBODY FORMULATION
#1530MODULATING RESPONSES TO CHECKPOINT INHIBITOR THERAPY
#1531Depleting tumor-specific tregs
#1532Antibodies against signal-regulatory protein alpha and methods of use
#1533NOVEL FUSION PROTEIN SPECIFIC FOR CD137 AND PD-L1
#1534Vista antagonist and methods of use
#1535COMBINATION THERAPY WITH GLUTAMINASE INHIBITORS AND IMMUNO-ONCOLOGY AGENTS
#1536Compositions and Methods For Treating Cancer with Anti-Renalase antibodies and Anti-PD1 antibodies
#1537METHODS AND COMBINATIONS FOR THE TREATMENT OF CANCER USING IMMUNE CHECKPOINT INHIBITOR ANTIBODIES
#1538Methods of Treating Cancer
#1539Targeting the Non-Canonical NFkB Pathway in Cancer Immunotherapy
#1540CONDITIONALLY ACTIVATED TARGET-BINDING MOLECULES
#1541Anti-PD-1 antibodies
#1542Targeted IL-12 heterodimeric Fc-fusion proteins
#1543COMPOSITIONS OF POLYMERIC MICRODEVICES AND METHODS OF USE THEREOF IN CANCER IMMUNOTHERAPY
#1544Methods of Treating Cancer
#1545Nant cancer vaccine
#1546PHARMACOPROTEOMICS PLATFORM IDENTIFYING KINOME FEATURES REGULATING DRUG RESPONSE IN CANCER
#1547Method for improving thermal stability of antibody and method for producing modified antibody
#1548CD80 variant immunomodulatory proteins and uses thereof
#1549Anti-Vista Antibodies And Fragments, Uses Thereof, And Methods Of Identifying Same
#1550EXOSOME-TARGETING BISPECIFIC ANTIBODIES
#1551ANTI-B7H3 ANTIBODY-EXATECAN ANALOG CONJUGATE AND MEDICINAL USE THEREOF
#1552DOSING REGIMEN OF ANTI-LAG3 ANTIBODY AND COMBINATION THERAPY WITH ANTI-PD-1 ANTIBODY FOR TREATING CANCER
#1553Fc-epsilon car
#1554METHOD OF PRODUCING A VACCINE COMPOSITION AND USES THEREOF
#1555COMBINATION IMMUNOTHERAPIES
#1556Combination therapy using ascochlorin derivative
#1557Methods of treating solid tumors with CCR2 antagonists
#1558COMBINATION OF AN UROLITHIN WITH AN IMMUNOTHERAPY TREATMENT
#1559Bacterial biomarker
#1560High affinity B7-H6 antibodies and antibody fragments
#1561Affibody proteins specific for B7-H3 (CD276)
#1562METHODS OF TREATING CANCER USING PD-1 AXIS BINDING ANTAGONISTS AND TIGIT INHIBITORS
#1563COMBINATION OF A BIG-H3 ANTAGONIST AND AN IMMUNE CHECKPOINT INHIBITOR FOR THE TREATMENT OF SOLID TUMOR
#1564Human interleukin-2 conjugates biased for the interleukin-2 receptor beta GAMMAc dimer and conjugated to a nonpeptidic, water-soluble polymer
#1565Methods of treating and preventing breast cancer with S-equol
#1566Cancer therapy
#1567COMBINATION THERAPY FOR CANCER COMPRISING PD-1 AXIS BINDING ANTAGONIST AND IL6 ANTAGONIST
#1568NOVEL CANCER IMMUNOTHERAPY ANTIBODY COMPOSITIONS
#1569COMBINATION THERAPY FOR CANCER
#1570METHODS FOR DIAGNOSING AND TREATING CANCERS
#1571Guided combinational therapeutic antibody
#1572METHODS OF TREATING CANCER USING PD-1 AXIS BINDING ANTAGONISTS AND TIGIT INHIBITORS
#1573Combination therapy using an IL-20 antagonist and an immune checkpoint inhibitor
#1574Single domain binding molecule
#1575Compositions and methods of treating cancer with chimeric antigen receptors
#1576Antigen binding proteins that bind PD-L1
#1577Method for treating cervical cancer
#1578SILENCING TGF-BETA 1 and COX2 USING siRNAs DELIVERED in a POLYPEPTIDE NANOPARTICLE ALONE and in COMBINATION with IMMUNE CHECKPOINT INHIBITORS to TREAT CANCER
#1579Method of making exosomes from tumor cell/antigen presenting cell hybrid cells
#1580Methods and compositions comprising B7H3 chimeric antigen receptors
#1581PD-L1 TARGETING MOLECULES COMPRISING SHIGA TOXIN A SUBUNIT SCAFFOLDS
#1582Checkpoint blockade and microsatellite instability
#1583Checkpoint blockade and microsatellite instability
#1584IL-15 Variants and Uses Thereof
#1585NOVEL STRAINS HAVING EFFECTS OF PREVENTING OR TREATING CANCERS
#1586ELIMINATION OF PD-L1-POSITIVE MALIGNANCIES BY PD-L1 CHIMERIC ANTIGEN RECEPTOR-EXPRESSING NK CELLS
#1587Anti-VISTA antibodies and fragments
#1588Super Versatile Method for Imparting New Binding Specificity to Antibody
#1589COMPOSITIONS AND METHODS RELATED TO ENGINEERED Fc-ANTIGEN BINDING DOMAIN CONSTRUCTS
#1590ANTI-HUMAN VISTA ANTIBODIES AND USE THEREOF
#1591ANTI-HUMAN VISTA ANTIBODIES AND USE THEREOF
#1592COMPOSITIONS CONTAINING ACTIVATABLE ANTIBODIES
#1593PHARMACEUTICAL COMBINATION FOR THE TREATMENT OF CANCER
#1594ELIMINATION OF PD-L1-POSITIVE MALIGNANCIES BY PD-L1 CHIMERIC ANTIGEN RECEPTOR-EXPRESSING NK CELLS
#1595SYSTEMS, METHODS, AND KITS FOR DIAGNOSTICS AND TREATMENT OF VIRAL RESPIRATORY INFECTION
#1596COEXPRESSION AND PURIFICATION METHOD OF CONDITIONALLY ACTIVATED BINDING PROTEINS
#1597Human PD-L1 antibodies
#1598ANTIBODIES THAT BIND CD277 AND USES THEREOF
#1599COMPOSITIONS AND METHODS FOR IMAGING
#1600Netrin G1 as a biomarker for enhancing tumor treatment efficacy
#1601PROGRAMMABLE BACTERIA FOR THE TREATMENT OF CANCER
#1602In vitro and xenograft anti-tumor activity of a halogenated-xanthene against refractory pediatric solid tumors
#1603COMPOSITIONS AND METHODS FOR IMMUNOTHERAPY TARGETING FLT3, PD-1, AND/OR PD-L1
#1604DIAGNOSTIC METHODS AND COMPOSITIONS FOR CANCER IMMUNOTHERAPY
#1605Antibody molecules
#1606COMBINATION OF LILRB1/2 PATHWAY INHIBITORS AND PD-1 PATHWAY INHIBITORS
#1607Splicing modulator antibody-drug conjugates and methods of use
#1608Systems, methods, and kits for diagnostics and treatment of viral respiratory infection
#1609CANCER THERAPY
#1610METHODS FOR TREATMENT AND DIAGNOSIS OF CANCER BY TARGETING GLYCOPROTEIN A REPETITIONS PREDOMINANT (GARP) AND FOR PROVIDING EFFECTIVE IMMUNOTHERAPY ALONE OR IN COMBINATION
#1611ANTIBODIES
#1612HISTAMINE DIHYDROCHLORIDE COMBINATIONS AND USES THEREOF
#1613Treatment of metastatic brain tumor by administration of an antibody-drug conjugate
#1614Sequential treatment of cancers using 6-thio-dG, checkpoint inhibitors and radiation therapy
#1615ANTIBODY MOLECULES TO PD-L1 AND USES THEREOF
#1616Multispecific binding constructs against checkpoint molecules and uses thereof
#1617COMPOSITIONS AND METHODS RELATED TO ENGINEERED FC-ANTIGEN BINDING DOMAIN CONSTRUCTS
#1618MULTIMERIC T-CELL MODULATORY POLYPEPTIDES AND METHODS OF USE THEREOF
#1619Siglec-9 ECD fusion molecules
#1620Compositions comprising an anti-LAG-3 antibody or an anti-LAG-3 antibody and an anti-PD-1 or anti-PD-L1 antibody
#1621BETA-GLUCAN METHODS AND COMPOSITIONS THAT AFFECT THE TUMOR MICROENVIRONMENT
#1622Methods for the detection and treatment of classes of hepatocellular carcinoma responsive to immunotherapy
#1623OX-40 AGONIST, PD-1 PATHWAY INHIBITOR AND CTLA-4 INHIBITOR COMBINATION FOR USE IN A METHOD OF TREATING A CANCER OR A SOLID TUMOR
#1624BINDING AGENTS BINDING TO PD-L1 AND CD137 AND USE THEREOF
#1625Anti-PD-L1 antibody
#1626RECOMBINANT TRANSMEMBRANE DOMAIN-DEFICIENT STING AS BIOMIMETIC PROTEIN CARRIER FOR CGAMP ENHANCED CANCER IMMUNOTHERAPY
#1627Nectin-4 antibody conjugates and uses thereof
#1628PD-1 and CTLA-4 Dual Inhibitor Peptides
#1629INACTIVATION OF DNA REPAIR AS AN ANTICANCER THERAPY
#1630Therapeutic bacterial composition
#1631BINDING AGENTS BINDING TO PD-L1 AND CD137 AND USE THEREOF
#1632Antibody inducing immune tolerance, induced lymphocyte, and cell therapy agent therapeutic method using induced lymphocyte
#1633Anti-PD-L1 antibodies
#1634Compositions and methods for the treatment of cancer characterized with PCSK9 expression
#1635Solid forms of an azolopyrimidine compound
#1636METHODS AND KITS FOR TREATING PAIN
#1637PREDICTION AND TREATMENT OF IMMUNOTHERAPEUTIC TOXICITY
#1638Anti-MerTK antibodies and methods of use thereof
#1639PROTEINS BINDING NKG2D, CD16, AND EGFR, CCR4, OR PD-L1
#1640Blocking type PD-L1 single-domain camel antibody and application thereof
#1641Treatment of LAG-3 positive tumors
#1642Method for eliciting infectious immunological tolerance
#1643Human antibodies that bind Lymphocyte Activation Gene-3 (LAG-3), and uses thereof
#1644Human antibodies that bind lymphocyte activation gene-3 (LAG-3), and uses thereof
#1645Human antibodies that bind lymphocyte activation gene-3 (LAG-3), and uses thereof
#1646Chimeric antigen receptor-modified NK-92 cells
#1647COMBINATION OF EZH2 INHIBITOR AND CHECKPOINT THERAPY FOR THE TREATMENT OF CANCER
#1648COMBINATION THERAPY FOR TREATING CANCER
#1649Methods for detecting and treating cancers having adenosine pathway activation
#1650Preparation Method for Attenuated Rhabdovirus and Application Thereof
#1651NOVEL BISPECIFIC AGONISTIC 4-1BB ANTIGEN BINDING MOLECULES
#1652DIAGNOSTIC AND THERAPEUTIC METHODS FOR KIDNEY CANCER
#1653PD-L 1-BINDING POLYPEPTIDE AND USE THEREOF
#1654VISTA Antagonist and Methods of Use
#1655BISPECIFIC IMMUNOMODULATORY ANTIBODIES THAT BIND COSTIMULATORY AND CHECKPOINT RECEPTORS
#1656MULTI-SPECIFIC ANTIBODY CONSTRUCTS
#1657Anti-CD112R compositions and methods
#1658Treatment of cancer
#1659ANTI-TIGIT ANTIBODIES AND METHODS OF USE
#1660Protein-containing aqueous liquid formulation
#1661COMBINATION THERAPIES COMPRISING CD137/HER2 BISPECIFIC AGENTS AND PD-1 AXIS INHIBITORS AND USES THEREOF
#1662EphA3 directed CAR-T cells for treatment of tumors
#1663Antitumor antagonists
#1664Dimers and use thereof
#1665COMBINED INHIBITION OF PD-1/PD-L1, TGFB AND DNA-PK FOR THE TREATMENT OF CANCER
#1666CHIMERIC ANTIGEN RECEPTOR TUMOR INFILTRATING LYMPHOCYTES
#1667PD1 and PDL-1 expression during progression from myelodysplastic syndrome to acute myelogenous leukemia
#1668MRNA display antibody library and methods
#1669Therapeutic targeting of non-cellular structures
#1670MODIFIED MITOCHONDRIA AND USE THEREOF
#1671INDUCTION OF ANTI-TUMORAL IMMUNE MICROENVIRONMENTS
#1672Genetically modified NK-92 cells and monoclonal antibodies for the treatment of cancer
#1673Anti-PD-L1/anti-CD47 bispecific antibody
#1674TREATMENT OF CANCER WITH COMBINATIONS OF IMMUNOREGULATORY AGENTS
#1675Antibody targeting CLDN18.2, bispecific antibody, ADC, and CAR, and applications thereof
#1676Multi-specific molecules
#1677CAR-T cells targeting glioma stem cells for the treatment of glioblastoma multiforme
#1678Modified anti-PD-L1 antibody and methods and uses for treating a neurodegenerative disease
#1679ANTI-PDL1 ANTIBODY FORMULATIONS
#1680Single-domain antibodies and variants thereof against PD-L1
#1681USE OF A CHECKPOINT INHIBITOR IN COMBINATION WITH ULTRALOW DOSE WHOLE BODY IRRADIATION
#1682Reducing systemic regulatory T cell levels or activity for treatment of amyotrophic lateral sclerosis
#1683Antibody binding TIM-3 and use thereof
#1684Urinary DNA Detection For Urothelial Cancer
#1685DOSING REGIMENS FOR TARGETED TGF-B INHIBITION FOR USE IN TREATING BILIARY TRACT CANCER
#1686Dual specificity antibodies to PD-L1 and PD-L2 and methods of use therefor
#1687Compositions and uses thereof for treating disease or condition
#1688NEOADJUVANT CANCER TREATMENT WITH IMMUNOTOXIN AND CHECKPOINT INHIBITOR COMBINATION
#1689IMMUNE CHECKPOINT THERAPY
#1690Compositions and methods for imaging
#1691Checkpoint inhibitor and a whole cell for use in cancer therapy
#1692CHECKPOINT INHIBITOR AND A WHOLE CELL MYCOBACTERIUM FOR USE IN CANCER THERAPY
#1693THERAPEUTIC AND DIAGNOSTIC METHODS FOR BLADDER CANCER
#1694Biomarkers associated with checkpoint immune therapy and methods of using same
#1695Bispecific antibodies and uses thereof
#1696Proteins specific for BAFF and B7RP1 and uses thereof
#1697PROTEINS BINDING NKG2D, CD16 AND A TUMOR-ASSOCIATED ANTIGEN
#1698Anti-B7-H6 antibody, fusion proteins, and methods of using the same
#1699Methods for modulating an immune response
#1700Synthetic multidomain peptide biomaterials that inhibit inducible nitric oxide synthase
#1701COMBINATION OF TOPOISOMERASE-I INHIBITORS WITH IMMUNOTHERAPY IN THE TREATMENT OF CANCER
#1702Treating and preventing microbial infections
#1703ANTI-CD27 AND ANTI-PD-L1 ANTIBODIES AND BISPECIFIC CONSTRUCTS
#1704B7-H7-BINDING AGENTS AND METHODS OF USE THEREOF
#1705COMBINATION PRODUCT FOR THE TREATMENT OF CANCER
#1706PHARMACEUTICAL COMPOSITION
#1707INCREASING RESPONSES TO CHECKPOINT INHIBITORS BY EXTRACORPOREAL APHERESIS
#1708FC-EPSILON CAR (Very imp commercially - in clinical trial)
#1709Multimeric IL-15-based molecules
#1710METHODS OF TREATING CANCERS USING PD-1 AXIS BINDING ANTAGONISTS AND TAXANES
#1711Reducing systemic regulatory T cell levels or activity for treatment of amyotrophic lateral sclerosis
#1712Modified bifunctional anti-human signal regulatory protein alpha (SIRPa) antibody and method of use thereof for treating cancer
#1713Antibodies specific for CD47, PD-L1, and uses thereof
#1714COMBINATION THERAPIES COMPRISING TIM-3-BASED CHIMERIC PROTEINS
#1715Pharmaceutical composition for combination therapy for preventing or treating cancer containing tumor-specific drug conjugate and anti-PD-L1 antibody as active ingredients
#17165-thiazolecarboxamide kinase inhibitor and uses thereof
#1717IMMUNOREACTANT CARRIER
#1718HEAT-INACTIVATED VACCINIA VIRUS AS A VACCINE IMMUNE ADJUVANT
#1719Microbiome biomarkers immunotherapy responsiveness: diagnostic, prognostic and therapeutic uses thereof
#1720CONJOINT THERAPY WITH GLUTAMINASE INHIBITORS
#1721Viral vectors encoding cancer/testis antigens for use in a method of prevention or treatment of cancer
#1722B7-H3 directed antibody drug conjugates
#1723Anti-vista antibodies and fragments, uses thereof, and methods of identifying same
#1724Anti-B7-H1 antibodies for treating tumors
#1725ANTIBODIES TO PROGRAMMED DEATH LIGAND (PD-L1) AND APPLICATION THEREOF
#1726ANTI-B7-H3 ANTIBODIES AND ANTIBODY DRUG CONJUGATES
#1727LEUCINE ZIPPER-BASED COMPOSITIONS AND METHODS OF USE
#1728MCL1 inhibitors
#1729GP96-BASED CANCER THERAPY
#1730T lymphocyte production methods and t lymphocytes produced thereby
#1731Binding agents binding to PD-L1 and CD137 and use thereof
#1732ANTI-PD-L1 ANTIBODIES
#1733PD-L1 BINDING AFFIMERS, AND USES RELATED THERETO
#1734Tumor immunotherapy target and application thereof
#1735Increasing responses to checkpoint inhibitors by extracorporeal apheresis
#1736Immunomodulatory IL-2 agents in combination with immune checkpoint inhibitors
#1737Engineered cells, T cell immune modulating antibodies and methods for using the same
#1738Immunoconjugates comprising signal regulatory protein alpha
#1739TARGETED HUMAN-INTERFERON FUSION PROTEINS
#1740PAK4 INHIBITORS AND METHODS OF USE
#1741CANCER THERAPY VIA A COMBINATION OF EPIGENETIC MODULATION AND IMMUNE MODULATION
#1742Compositions containing tucaresol or its analogs
#1743DETECTION OF IMMUNE CHECKPOINT MOLECULES BY DEGLYCOSYLATION
#1744THERAPEUTIC CONSTRUCTS FOR TREATING CANCER
#1745ENHANCING THE THERAPEUTIC ACTIVITY OF IMMUNE CHECKPOINT INHIBITOR
#1746Checkpoint blockade and microsatellite instability
#1747COMBINATION THERAPY USING A PEPTIDE
#1748Methods of treating cancer
#1749SKIN CANCER TREATMENT
#1750Method for predicting efficacy of anti-PD-1 antibody or anti-PD-L1 antibody therapy, method for evaluating cancer grade, and method for enhancing efficacy of anti-PD-1 antibody or anti-PD-L1 antibody therapy
#1751Beta-catenin inhibitors in cancer immunotherapy
#1752METHOD TO ASSESS SUITABILITY FOR CANCER IMMUNOTHERAPY
#1753Biomarkers for predicting tumor response to and toxicity of immunotherapy
#1754ANTICANCER COMBINATION THERAPY WITH CD73 ANTAGONIST ANTIBODY AND PD-1/PD-L1 AXIS ANTAGONIST ANTIBODY
#1755ANTI-CHEMOKIN LIKE RECEPTOR 1 ANTIBODIES AND THEIR THERAPEUTIC APPLICATIONS
#1756COMPOSITIONS AND METHODS RELATED TO ENGINEERED Fc-ANTIGEN BINDING DOMAIN CONSTRUCTS TARGETED TO PD-L1
#1757Fusion protein of interferon (IFN) and anti-PD-L1 antibody and use thereof
#1758Dosage Regimens For Anti-Pd-L1 Antibodies And Uses Thereof
#1759Human PD-L1-binding immunoglobulins
#1760IMMUNOTOXINS FOR USE IN TREATING CANCER
#1761Antigen binding proteins that bind PD-L1
#1762VISTA-Ig constructs and the use of VISTA-Ig for treatment of autoimmune, allergic and inflammatory disorders
#1763Cell-mediated transient delivery of immune-enhancing molecules into the tumor microenvironment
#1764Crystalline forms of 5-bromo-2,6-di(1H-pyrazol-1- yl)pyrimidin-4-amine and new salts
#1765Halogenated xanthene composition and method for treating hematologic cancers
#1766BIOMARKERS AND METHODS OF TREATING PD-1 AND PD-L1 RELATED CONDITIONS
#1767Antigen-specific T cells and uses thereof
#1768LYMPHOCYTE ANTIGEN CD5-LIKE (CD5L) MONOMER, HOMODIMER, AND INTERLEUKIN 12B (P40) HETERODIMER AGONISTS AND METHODS OF USE THEREOF
#1769ANTI-CD40 ANTIBODIES IN COMBINATION AND METHODS OF USE
#1770Anti-human PD-L1 antibodies and their uses
#1771Dual specificity antibodies to human PD-L1 and PD-L2 and methods of use therefor
#1772FC binding fragments comprising a PD-L1 antigen-binding site
#1773ANTI-VISTA ANTIBODIES AND METHODS OF USE
#1774Amino acid sequences that modulate the interaction between cells of the immune system
#1775BISPECIFIC SIGNALING AGENTS AND USES THEREOF
#1776Strains having effects of preventing or treating cancers
#1777Polypeptide-antibody complexes and uses thereof
#1778Methods of using bispecific molecules having immunoreactivity with PD-1 and CTLA-4
#1779Methods of treating PD-L1 expressing cancer
#1780Checkpoint blockade and microsatellite instability
#1781COMBINATION OF LIF INHIBITORS AND PD-1 AXIS INHIBITORS FOR USE IN TREATING CANCER
#1782PAN-CANCER T CELL EXHAUSTION GENES
#1783Thienoazepine immunoconjugates, and uses thereof
#1784COMBINATORIAL ANDROGEN DEPRIVATION WITH AN ANDROGEN RECEPTOR VACCINE
#1785COMBINATION COMPOSITIONS FOR IMMUNOTHERAPY
#1786Predictive peripheral blood biomarker for checkpoint inhibitors
#1787Anti-PD-L1 antibodies and use thereof
#1788Combining adenovirus and checkpoint inhibitors for treating cancer
#1789MODULATING RESPONSES TO CHECKPOINT INHIBITOR THERAPY
#1790Method of treating cancer with an anti-CCR8 that binds tumor infiltrating cells
#1791COMBINATION THERAPY WITH TARGETED TGF-B INHIBITION FOR TREATMENT OF ADVANCED NON-SMALL CELL LUNG CANCER
#1792KIR3DL3 as an HHLA2 receptor, anti-HHLA2 antibodies, and uses thereof
#1793ANTI-PD-L1 ANTIBODY AND USE THEREOF
#1794TREATMENT OF STAGE III NSCLC AND MITIGATION OF PATHOLOGICAL CONDITIONS ASSOCIATED WITH THE TREATMENT
#1795INTRACELLULAR DELIVERY OF BIOMOLECULES TO MODIFY IMMUNE RESPONSE
#1796TREATMENT USING CYTOKINE ENCODING RNA
#1797PLAP-CAR-effector cells
#1798Multi-specific binding proteins for cancer treatment
#1799Antibodies binding 4-1BB and uses thereof
#1800Checkpoint blockade and microsatellite instability